Published in PLoS Pathog on May 15, 2014
Clinical Investigation of Erlotinib as an HCV Entry Inhibitor | NCT01835938
RACK1 controls IRES-mediated translation of viruses. Cell (2014) 0.95
Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection. Viruses (2015) 0.91
New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect Dis (2016) 0.91
The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol (2014) 0.89
EFTUD2 Is a Novel Innate Immune Regulator Restricting Hepatitis C Virus Infection through the RIG-I/MDA5 Pathway. J Virol (2015) 0.89
Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses (2015) 0.84
Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach. J Virol (2015) 0.83
Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein. Gut (2015) 0.81
Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes. Cell Rep (2016) 0.78
Inhibition of Hepatitis C Virus in Mice by a Small Interfering RNA Targeting a Highly Conserved Sequence in Viral IRES Pseudoknot. PLoS One (2016) 0.78
Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies. Expert Rev Vaccines (2016) 0.77
The Serum Very-Low-Density Lipoprotein Serves as a Restriction Factor against Hepatitis C Virus Infection. J Virol (2015) 0.76
Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication. Int J Nanomedicine (2015) 0.76
A robust model of natural hepatitis C infection using hepatocyte-like cells derived from human induced pluripotent stem cells as a long-term host. Virol J (2016) 0.75
A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific Manner. Sci Rep (2017) 0.75
Identification of Entry Factors Involved in Hepatitis C Virus Infection Based on Host-Mimicking Short Linear Motifs. PLoS Comput Biol (2017) 0.75
Modelling the Impact of Cell-To-Cell Transmission in Hepatitis B Virus. PLoS One (2016) 0.75
Characterization of HCV envelope diversification from acute to chronic infection using SMRT sequencing within a sexually-transmitted hepatitis C virus cluster. J Virol (2017) 0.75
Editorial on "Broadly neutralizing antibodies abrogate established hepatitis C virus infection" published in Science Translational Medicine on 17th September 2014. Ann Transl Med (2015) 0.75
Oligonucleotide-Lipid Conjugates Forming G-Quadruplex Structures Are Potent and Pangenotypic Hepatitis C Virus Entry Inhibitors In Vitro and Ex Vivo. Antimicrob Agents Chemother (2017) 0.75
Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clin Microbiol Infect (2016) 0.75
Viral effects on the content and function of extracellular vesicles. Nat Rev Microbiol (2017) 0.75
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A (2006) 6.87
Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med (2012) 6.44
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med (2013) 6.08
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife (2012) 5.18
Current and future therapies for hepatitis C virus infection. N Engl J Med (2013) 4.25
Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol (2008) 3.79
Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol (2006) 3.75
Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med (2011) 3.74
Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med (2013) 3.52
Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol (2010) 3.44
HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science (2010) 3.29
Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology (2009) 3.10
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology (2008) 3.09
Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature (2011) 3.08
Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol (2005) 2.85
Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med (2010) 2.82
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother (2010) 2.28
Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology (2007) 2.25
Antiviral strategies in hepatitis C virus infection. J Hepatol (2012) 2.25
Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology (2011) 2.24
Hepatitis B therapy. Nat Rev Gastroenterol Hepatol (2011) 2.23
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol (2009) 1.87
Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog (2012) 1.79
Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog (2012) 1.74
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67
Fresh approaches to anti-infective therapies. Sci Transl Med (2012) 1.67
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology (2010) 1.58
Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog (2009) 1.56
Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol (2012) 1.50
Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol (2008) 1.48
Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells. J Virol (2006) 1.47
Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α. Gastroenterology (2010) 1.42
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe (2013) 1.37
NS5A inhibitors in the treatment of hepatitis C. J Hepatol (2013) 1.36
Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology (2012) 1.31
Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges. J Hepatol (2012) 1.22
Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J Virol (2013) 1.20
Treatment of chronic hepatitis C: current and future. Curr Top Microbiol Immunol (2013) 1.14
Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J Infect Dis (2012) 1.13
Cell-to-cell transmission of viruses. Curr Opin Virol (2012) 1.13
Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler Thromb Vasc Biol (2009) 1.11
The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology (2011) 1.10
The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology (2012) 1.07
A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission. PLoS One (2013) 1.04
Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J Infect Dis (2013) 0.99
Isolate-dependent use of claudins for cell entry by hepatitis C virus. Hepatology (2014) 0.99
Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response. Gastroenterology (2012) 0.98
Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Gut (2013) 0.98
An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. Hepatology (2013) 0.96
Early infection events highlight the limited transmissibility of hepatitis C virus in vitro. J Hepatol (2013) 0.90
Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses. Antimicrob Agents Chemother (2012) 0.90
Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV/HCV coinfected patients. Virus Res (2013) 0.90
Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies. J Virol (2013) 0.89
Treatment failure with new hepatitis C drugs. Expert Opin Pharmacother (2012) 0.87
Treatment decisions and contemporary versus pending treatments for hepatitis C. Nat Rev Gastroenterol Hepatol (2013) 0.84
Entry inhibitors and future treatment of hepatitis C. Antiviral Res (2014) 0.82
Fc block treatment, dead cells exclusion, and cell aggregates discrimination concur to prevent phenotypical artifacts in the analysis of subpopulations of tumor-infiltrating CD11b(+) myelomonocytic cells. Cytometry A (2010) 0.78